Growth factor pathways in development and progression of hepatocellular carcinoma

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 4, 2012, Pages 1487-1515

  Nalesnik, Michael Andrew ^a   Michalopoulos, George Konstantine ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Growth Factors; Hepatocellular carcinoma; Hepatocyte; Liver; Review

Indexed keywords

AVE 1642; BIIB 022; BRIVANIB; CABOZANTINIB; CETUXIMAB; CIXUTUMUMAB; DALOTUZUMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FLUINDOSTATIN; FORETINIB; GEFITINIB; GEMCITABINE; INC 280; LAPATINIB; LINIFANIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NINTEDANIB; OXALIPLATIN; PANITUMUMAB; PEXASTIMOGENE DEVACIREPVEC; PLATELET DERIVED GROWTH FACTOR RECEPTOR; QUINAZOLINE; SCATTER FACTOR; SOMATOMEDIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB; SIGNAL PEPTIDE;

ARTICLE; CLINICAL TRIAL; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; ANIMAL; LIVER TUMOR; METABOLISM; PATHOLOGY; REVIEW;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL;

EID: 84869455179     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s348     Document Type: Article

References (245)

1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward and D. Forman: Global cancer statistics. CA Cancer J Clin, 61(2), 69-90 (2011))
2. J. Broten, G. Michalopoulos, B. Petersen and J. Cruise: Adrenergic stimulation of hepatocyte growth factor expression. Biochem Biophys Res Commun, 262(1), 76-9 (1999)) (Pubitemid 29412626)
3. V. Orian-Rousseau, L. Chen, J. P. Sleeman, P. Herrlich and H. Ponta: CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev, 16(23), 3074-86 (2002)) (Pubitemid 35424194)
4. V. Orian-Rousseau, H. Morrison, A. Matzke, T. Kastilan, G. Pace, P. Herrlich and H. Ponta: Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell, 18(1), 76-83 (2007)) (Pubitemid 46066712)
5. L. Trusolino, A. Bertotti and P. M. Comoglio: MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol, 11(12), 834-48 (2010))
6. H. Kataoka, S. Miyata, S. Uchinokura and H. Itoh: Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev, 22(2-3), 223-36 (2003)) (Pubitemid 36561059)
7. S. A. Lee, S. Ladu, M. Evert, F. Dombrowski, V. De Murtas, X. Chen and D. F. Calvisi: Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology, 52(2), 506-17 (2010))
8. A. Kiss, N. J. Wang, J. P. Xie and S. S. Thorgeirsson: Analysis of transforming growth factor (TGF)- alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res, 3(7), 1059-66 (1997)) (Pubitemid 27319751)
9. C. Selden, S. Farnaud, S. F. Ding, N. Habib, C. Foster and H. J. Hodgson: Expression of hepatocyte growth factor mRNA, and c-met mRNA (hepatocyte growth factor receptor) in human liver tumours. J Hepatol, 21(2), 227-34 (1994)) (Pubitemid 24270550)
10. E. K. Tung, C. M. Wong, T. O. Yau, J. M. Lee, Y. P. Ching and I. O. Ng: HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions. Int J Cancer, 124(8), 1811-9 (2009))
11. D. N. Finegold, V. Schacht, M. A. Kimak, E. C. Lawrence, E. Foeldi, J. M. Karlsson, C. J. Baty and R. E. Ferrell: HGF and MET mutations in primary and secondary lymphedema. Lymphat Res Biol, 6(2), 65-8 (2008)) (Pubitemid 351873446)
12. L. S. Schultz, J. A. Cartmill, J. N. Graber and D. F. Hickok: Laparolithic cholecystectomy: laboratory data and first clinical case. J Clin Laser Med Surg, 11(3), 136-7 (1993))
13. L. Boix, J. L. Rosa, F. Ventura, A. Castells, J. Bruix, J. Rodes and R. Bartrons: c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology, 19(1), 88-91 (1994)) (Pubitemid 24020476)
14. K. Suzuki, N. Hayashi, Y. Yamada, H. Yoshihara, Y. Miyamoto, Y. Ito, T. Ito, K. Katayama, Y. Sasaki, A. Ito and et al.: Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology, 20(5), 1231-6 (1994))
15. A. M. Dulak, C. T. Gubish, L. P. Stabile, C. Henry and J. M. Siegfried: HGF-independent potentiation of EGFR action by c-Met. Oncogene (2011))
16. K. Breuhahn, T. Longerich and P. Schirmacher: Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene, 25(27), 3787-800 (2006)) (Pubitemid 43980474)
17. P. Moinzadeh, K. Breuhahn, H. Stutzer and P. Schirmacher: Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade - results of an explorative CGH meta-analysis. Br J Cancer, 92(5), 935-41 (2005)) (Pubitemid 40462642)
18. B. Xie, R. Xing, P. Chen, Y. Gou, S. Li, J. Xiao and J. Dong: Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. J Surg Res, 162(2), 231-8 (2010))
19. W. S. Park, S. M. Dong, S. Y. Kim, E. Y. Na, M. S. Shin, J. H. Pi, B. J. Kim, J. H. Bae, Y. K. Hong, K. S. Lee, S. H. Lee, N. J. Yoo, J. J. Jang, S. Pack, Z. Zhuang, L. Schmidt, B. Zbar and J. Y. Lee: Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res, 59(2), 307-10 (1999)) (Pubitemid 29048858)
20. J. C. Henry, J. K. Park, J. Jiang, J. H. Kim, D. M. Nagorney, L. R. Roberts, S. Banerjee and T. D. Schmittgen: miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun, 403(1), 120-5 (2010))
21. F. Fornari, M. Milazzo, P. Chieco, M. Negrini, G. A. Calin, G. L. Grazi, D. Pollutri, C. M. Croce, L. Bolondi and L. Gramantieri: MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res, 70(12), 5184-93 (2010))
22. G. K. Michalopoulos: HGF in liver regeneration and tumor promotion. Prog Clin Biol Res, 391, 179-85 (1995))
23. T. Nagai, T. Arao, K. Furuta, K. Sakai, K. Kudo, H. Kaneda, D. Tamura, K. Aomatsu, H. Kimura, Y. Fujita, K. Matsumoto, N. Saijo, M. Kudo and K. Nishio: Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther, 10(1), 169-77 (2011))
24. Y. C. Wang, G. L. Xu, W. D. Jia, S. J. Han, W. H. Ren, W. Wang, W. B. Liu, C. H. Zhang and H. Chen: Estrogen Suppresses Metastasis in Rat Hepatocellular Carcinoma through Decreasing Interleukin-6 and Hepatocyte Growth Factor Expression. Inflammation (2011))
25. J. Okano, G. Shiota and H. Kawasaki: Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver, 19(2), 151-9 (1999)) (Pubitemid 29139769)
26. M. Daveau, M. Scotte, A. Francois, C. Coulouarn, G. Ros, Y. Tallet, M. Hiron, M. F. Hellot and J. P. Salier: Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog, 36(3), 130-41 (2003)) (Pubitemid 36314790)
27. T. Ueki, J. Fujimoto, T. Suzuki, H. Yamamoto and E. Okamoto: Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology, 25(3), 619-23 (1997)) (Pubitemid 27106443)
28. P. Vejchapipat, P. Tangkijvanich, A. Theamboonlers, V. Chongsrisawat, S. Chittmittrapap and Y. Poovorawan: Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol, 39(12), 1182-8 (2004))
29. Y. Liu, J. He, C. Li, R. Benitez, S. Fu, J. Marrero and D. M. Lubman: Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res, 9(2), 798-805 (2010))
30. S. Costantini, F. Capone, E. Guerriero, P. Maio, G. Colonna and G. Castello: Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis. Eur Cytokine Netw, 21(4), 251-6 (2010))
31. C. Wu, Z. Tang, W. Fan, W. Zhu, C. Wang, E. Somoza, N. Owino, R. Li, P. C. Ma and Y. Wang: In vivo positron emission tomography (PET) imaging of mesenchymalepithelial transition (MET) receptor. J Med Chem, 53(1), 139-46 (2010))
32. I. Kenessey, M. Keszthelyi, Z. Kramer, J. Berta, A. Adam, J. Dobos, M. Mildner, B. Flachner, S. Cseh, G. Barna, B. Szokol, L. Orfi, G. Keri, B. Dome, W. Klepetko, J. Timar and J. Tovari: Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets, 10(3), 332-42 (2010))
33. S. Eathiraj, R. Palma, E. Volckova, M. Hirschi, D. S. France, M. A. Ashwell and T. C. Chan: Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-MET) autophosphorylation by ARQ 197. J Biol Chem (2011))
34. F. Qian, S. Engst, K. Yamaguchi, P. Yu, K. A. Won, L. Mock, T. Lou, J. Tan, C. Li, D. Tam, J. Lougheed, F. M. Yakes, F. Bentzien, W. Xu, T. Zaks, R. Wooster, J. Greshock and A. H. Joly: Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res, 69(20), 8009-16 (2009))
35. X. Xin, S. Yang, G. Ingle, C. Zlot, L. Rangell, J. Kowalski, R. Schwall, N. Ferrara and M. E. Gerritsen: Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol, 158(3), 1111-20 (2001)) (Pubitemid 32221803)
36. S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano and P. M. Comoglio: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 3(4), 347-61 (2003)) (Pubitemid 38340304)
37. J. Qi, M. A. McTigue, A. Rogers, E. Lifshits, J. G. Christensen, P. A. Janne and J. A. Engelman: Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res, 71(3), 1081-91 (2011))
38. T. Hisaka, H. Yano, M. Haramaki, I. Utsunomiya and M. Kojiro: Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation. Int J Oncol, 14(3), 453-60 (1999))
39. L. G. Komuves, A. Feren, A. L. Jones and E. Fodor: Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem, 48(6), 821-30 (2000)) (Pubitemid 30366616)
40. Y. Ito, T. Takeda, Y. Sasaki, M. Sakon, T. Yamada, S. Ishiguro, S. Imaoka, M. Tsujimoto, S. Higashiyama, M. Monden and N. Matsuura: Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract, 197(2), 95-100 (2001)) (Pubitemid 32194502)
41. S. Whittaker, R. Marais and A. X. Zhu: The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 29(36), 4989-5005 (2010))
42. T. Y. Lee, K. T. Kim and S. Y. Han: Expression of ErbB receptor proteins and TGF-alpha during diethylnitrosamine-induced hepatocarcinogenesis in the rat liver. Korean J Hepatol, 13(1), 70-80 (2007))
43. Z. Q. Zou, Y. P. Ding, B. Long, J. G. Yuh, A. L. Xu, Z. W. Lang, S. Y. Zou, Y. D. Liu, K. Ding and Y. Y. Li: Gpc- 3 is a notable diagnostic, prognostic and a latent targeted therapy marker in hepatocellular carcinoma. Hepatogastroenterology, 57(102-103), 1285-90 (2010))
44. W. S. Moon, H. S. Park, K. H. Yu, M. Y. Park, K. R. Kim, K. Y. Jang, J. S. Kim and B. H. Cho: Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. Hum Pathol, 37(10), 1324-32 (2006)) (Pubitemid 44380277)
45. K. Yamaguchi, B. I. Carr and M. A. Nalesnik: Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J Surg Oncol, 58(4), 240-5 (1995))
46. Y. Morimitsu, C. C. Hsia, M. Kojiro and E. Tabor: Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum Pathol, 26(10), 1126-32 (1995))
47. J. D. Collier, K. Guo, W. J. Gullick, M. F. Bassendine and A. D. Burt: Expression of transforming growth factor alpha in human hepatocellular carcinoma. Liver, 13(3), 151-5 (1993)) (Pubitemid 23228711)
48. E. Tabor: Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol, 42(4), 357-65 (1994)) (Pubitemid 24128130)
49. C. C. Hsia, S. S. Thorgeirsson and E. Tabor: Expression of hepatitis B surface and core antigens and transforming growth factor-alpha in "oval cells" of the liver in patients with hepatocellular carcinoma. J Med Virol, 43(3), 216-21 (1994)) (Pubitemid 24227589)
50. E. Tabor, M. Farshid, A. Di Bisceglie and C. C. Hsia: Increased expression of transforming growth factor alpha after transfection of a human hepatoblastoma cell line with the hepatitis B virus. J Med Virol, 37(4), 271-3 (1992))
51. C. C. Hsia, C. A. Axiotis, A. M. Di Bisceglie and E. Tabor: Transforming growth factor-alpha in human hepatocellular carcinoma and coexpression with hepatitis B surface antigen in adjacent liver. Cancer, 70(5), 1049-56 (1992))
52. J. H. Kim and H. M. Rho: Activation of the human transforming growth factor alpha (TGF-alpha) gene by the hepatitis B viral X protein (HBx) through AP-2 sites. Mol Cell Biochem, 231(1-2), 155-61 (2002)) (Pubitemid 34257234)
53. M. Ono, K. Morisawa, J. Nie, K. Ota, T. Taniguchi, T. Saibara and S. Onishi: Transactivation of transforming growth factor alpha gene by hepatitis B virus preS1. Cancer Res, 58(9), 1813-6 (1998)) (Pubitemid 28217452)
54. Y. Inui, S. Higashiyama, S. Kawata, S. Tamura, J. Miyagawa, N. Taniguchi and Y. Matsuzawa: Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology, 107(6), 1799-804 (1994)) (Pubitemid 24357636)
55. E. Miyoshi, S. Higashiyama, T. Nakagawa, K. Suzuki, M. Horimoto, N. Hayashi, H. Fusamoto, T. Kamada and N. Taniguchi: High expression of heparin-binding EGF-like growth factor in rat hepatocarcinogenesis. Int J Cancer, 68(2), 215-8 (1996)) (Pubitemid 26380126)
56. S. Y. Hsieh, J. R. He, C. Y. Hsu, W. J. Chen, R. Bera, K. Y. Lin, T. C. Shih, M. C. Yu, Y. J. Lin, C. J. Chang, W. H. Weng and S. F. Huang: Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma. Hepatology, 53(2), 504-16 (2011))
57. E. M. Webber, J. C. Wu, L. Wang, G. Merlino and N. Fausto: Overexpression of transforming growth factoralpha causes liver enlargement and increased hepatocyte proliferation in transgenic mice. Am J Pathol, 145(2), 398-408 (1994)) (Pubitemid 24245840)
58. J. Y. Baek, S. M. Morris, J. Campbell, N. Fausto, M. M. Yeh and W. M. Grady: TGF-beta inactivation and TGFalpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer. Int J Cancer, 127(5), 1060-71 (2010))
59. E. Santoni-Rugiu, M. R. Jensen, V. M. Factor and S. S. Thorgeirsson: Acceleration of c-myc-induced hepatocarcinogenesis by Co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption. Am J Pathol, 154(6), 1693-700 (1999)) (Pubitemid 29262851)
60. L. M. Sargent, X. Zhou, C. L. Keck, N. D. Sanderson, D. B. Zimonjic, N. C. Popescu and S. S. Thorgeirsson: Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver. Am J Pathol, 154(4), 1047-55 (1999)) (Pubitemid 29169739)
61. L. G. Cavin, F. Wang, V. M. Factor, S. Kaur, M. Venkatraman, S. S. Thorgeirsson and M. Arsura: Transforming growth factor-alpha inhibits the intrinsic pathway of c-Myc-induced apoptosis through activation of nuclear factor-kappaB in murine hepatocellular carcinomas. Mol Cancer Res, 3(7), 403-12 (2005)) (Pubitemid 41045590)
62. F. Liu, H. L. Qi and H. L. Chen: Effects of all-trans retinoic acid and epidermal growth factor on the expression of nm23-H1 in human hepatocarcinoma cells. J Cancer Res Clin Oncol, 126(2), 85-90 (2000)) (Pubitemid 30062965)
63. Z. H. Xian, S. H. Zhang, W. M. Cong, W. Q. Wu and M. C. Wu: Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma. J Clin Pathol, 58(5), 500-3 (2005))
64. H. Nakamura, H. Aoki, O. Hino and M. Moriyama: HCV core protein promotes heparin binding EGF-like growth factor expression and activates Akt. Hepatol Res (2011))
65. L. Caja, C. Ortiz, E. Bertran, M. M. Murillo, M. J. Miro-Obradors, E. Palacios and I. Fabregat: Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis. Cell Signal, 19(4), 683-94 (2007)) (Pubitemid 46275361)
66. C. Lagaudriere-Gesbert, F. Le Naour, S. Lebel-Binay, M. Billard, E. Lemichez, P. Boquet, C. Boucheix, H. Conjeaud and E. Rubinstein: Functional analysis of four tetraspans, CD9, CD53, CD81, and CD82, suggests a common role in costimulation, cell adhesion, and migration: only CD9 upregulates HB-EGF activity. Cell Immunol, 182(2), 105-12 (1997)) (Pubitemid 28133998)
67. K. Kanetaka, M. Sakamoto, Y. Yamamoto, S. Yamasaki, F. Lanza, T. Kanematsu and S. Hirohashi: Overexpression of tetraspanin CO-029 in hepatocellular carcinoma. J Hepatol, 35(5), 637-42 (2001)) (Pubitemid 33078274)
68. H. L. LaMarca and J. M. Rosen: Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage. Breast Cancer Res, 9(4), 304 (2007))
69. V. Miceli, M. Cervello, A. Azzolina, G. Montalto, M. Calabro and G. Carruba: Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells. Ann N Y Acad Sci, 1155, 252-6 (2009))
70. J. Castillo, S. Goni, M. U. Latasa, M. J. Perugorria, A. Calvo, J. Muntane, P. Bioulac-Sage, C. Balabaud, J. Prieto, M. A. Avila and C. Berasain: Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors. Gastroenterology, 137(5), 1805-15 e1-4 (2009))
71. Y. M. Lee, M. H. Bae, O. H. Lee, E. J. Moon, C. K. Moon, W. H. Kim and K. W. Kim: Synergistic induction of in vivo angiogenesis by the combination of insulin-like growth factor-II and epidermal growth factor. Oncol Rep, 12(4), 843-8 (2004))
72. C. Han, G. K. Michalopoulos and T. Wu: Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol, 207(1), 261-70 (2006))
73. X. Tan, U. Apte, A. Micsenyi, E. Kotsagrelos, J. H. Luo, S. Ranganathan, D. K. Monga, A. Bell, G. K. Michalopoulos and S. P. Monga: Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology, 129(1), 285-302 (2005)) (Pubitemid 41002061)
74. K. K. Tanabe, A. Lemoine, D. M. Finkelstein, H. Kawasaki, T. Fujii, R. T. Chung, G. Y. Lauwers, Y. Kulu, A. Muzikansky, D. Kuruppu, M. Lanuti, J. M. Goodwin, D. Azoulay and B. C. Fuchs: Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. Jama, 299(1), 53-60 (2008))
75. Y. Li, Q. Xie, F. Lu, J. Zhao, P. Mao, Z. Li, S. Liu and H. Zhuang: Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver Int, 30(1), 112-8 (2010))
76. K. Chen, Y. Wei, H. Yang and B. Li: Epidermal growth factor +61 g/a polymorphism and the risk of hepatocellular carcinoma in a chinese population. Genet Test Mol Biomarkers, 15(4), 251-5 (2011))
77. P. Qi, H. Wang, Y. M. Chen, X. J. Sun, Y. Liu and C. F. Gao: No association of EGF 5'UTR variant A61G and hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. Pathology, 41(6), 555-60 (2009))
78. N. Yoneda, Y. Sato, A. Kitao, H. Ikeda, S. Sawada-Kitamura, M. Miyakoshi, K. Harada, M. Sasaki, O. Matsui and Y. Nakanuma: Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. Lab Invest, 91(2), 262-72 (2011))
79. Y. Ito, T. Takeda, S. Higashiyama, M. Sakon, K. I. Wakasa, M. Tsujimoto, M. Monden and N. Matsuura: Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep, 8(4), 903-7 (2001)) (Pubitemid 33758146)
80. A. Huether, M. Hopfner, V. Baradari, D. Schuppan and H. Scherubl: EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol, 70(11), 1568-78 (2005)) (Pubitemid 41540350)
81. B. C. Fuchs, T. Fujii, J. D. Dorfman, J. M. Goodwin, A. X. Zhu, M. Lanuti and K. K. Tanabe: Epithelial-tomesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res, 68(7), 2391-9 (2008))
82. D. L. Wheeler, E. F. Dunn and P. M. Harari: Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol, 7(9), 493-507 (2010))
83. A. X. Zhu, K. Stuart, L. S. Blaszkowsky, A. Muzikansky, D. P. Reitberg, J. W. Clark, P. C. Enzinger, P. Bhargava, J. A. Meyerhardt, K. Horgan, C. S. Fuchs and D. P. Ryan: Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer, 110(3), 581-9 (2007)) (Pubitemid 47106147)
84. A. Asnacios, L. Fartoux, O. Romano, C. Tesmoingt, S. S. Louafi, T. Mansoubakht, P. Artru, T. Poynard, O. Rosmorduc, M. Hebbar and J. Taieb: Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer, 112(12), 2733-9 (2008))
85. P. J. O'Dwyer, B. J. Giantonio, D. E. Levy, J. S. Kauh, D. B. Fitzgerald and A. B. Benson: Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's study E1203. [Abstract]. J Clin Oncol, 24 (Suppl 18), A-4143, 213s (2006))
86. Z. Li, M. Xu, S. Xing, W. T. Ho, T. Ishii, Q. Li, X. Fu and Z. J. Zhao: Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem, 282(6), 3428-32 (2007)) (Pubitemid 47084420)
87. M. B. Thomas, R. Chadha, K. Glover, X. Wang, J. Morris, T. Brown, A. Rashid, J. Dancey and J. L. Abbruzzese: Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer, 110(5), 1059-67 (2007)) (Pubitemid 47312872)
88. M. B. Thomas, J. S. Morris, R. Chadha, M. Iwasaki, H. Kaur, E. Lin, A. Kaseb, K. Glover, M. Davila and J. Abbruzzese: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol, 27(6), 843-50 (2009))
89. R. K. Ramanathan, C. P. Belani, D. A. Singh, M. Tanaka, H. J. Lenz, Y. Yen, H. L. Kindler, S. Iqbal, J. Longmate, P. C. Mack, G. Lurje, R. Gandour-Edwards, J. Dancey and D. R. Gandara: A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol, 64(4), 777-83 (2009))
90. T. Bekaii-Saab, J. Markowitz, N. Prescott, W. Sadee, N. Heerema, L. Wei, Z. Dai, A. Papp, A. Campbell, K. Culler, C. Balint, B. O'Neil, R. M. Lee, M. Zalupski, J. Dancey, H. Chen, M. Grever, C. Eng and M. Villalona-Calero: A multiinstitutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res, 15(18), 5895-901 (2009))
91. S. Blumenthal: From insulin and insulin-like activity to the insulin superfamily of growth-promoting peptides: a 20thcentury odyssey. Perspect Biol Med, 53(4), 491-508 (2010))
92. P. P. Luedi, F. S. Dietrich, J. R. Weidman, J. M. Bosko, R. L. Jirtle and A. J. Hartemink: Computational and experimental identification of novel human imprinted genes. Genome Res, 17(12), 1723-30 (2007)) (Pubitemid 351359996)
93. Z. Z. Dong, D. F. Yao, D. B. Yao, X. H. Wu, W. Wu, L. W. Qiu, D. R. Jiang, J. H. Zhu and X. Y. Meng: Expression and alteration of insulin-like growth factor IImessenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol, 11(30), 4655-60 (2005)) (Pubitemid 41179518)
94. E. Cariani, C. Lasserre, D. Seurin, B. Hamelin, F. Kemeny, D. Franco, M. P. Czech, A. Ullrich and C. Brechot: Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res, 48(23), 6844-9 (1988))
95. A. Tannapfel, K. Anhalt, P. Hausermann, F. Sommerer, M. Benicke, D. Uhlmann, H. Witzigmann, J. Hauss and C. Wittekind: Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol, 201(2), 238-49 (2003)) (Pubitemid 37258935)
96. T. Ubagai, T. Kikuchi, T. Fukusato and Y. Ono: Aflatoxin B1 modulates the insulin-like growth factor-2 dependent signaling axis. Toxicol In Vitro, 24(3), 783-9 (2010))
97. J. H. Luo, B. Ren, S. Keryanov, G. C. Tseng, U. N. Rao, S. P. Monga, S. Strom, A. J. Demetris, M. Nalesnik, Y. P. Yu, S. Ranganathan and G. K. Michalopoulos: Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology, 44(4), 1012-24 (2006)) (Pubitemid 46489565)
98. T. Hanafusa, Y. Yumoto, K. Nouso, H. Nakatsukasa, T. Onishi, T. Fujikawa, M. Taniyama, S. Nakamura, M. Uemura, Y. Takuma, E. Yumoto, T. Higashi and T. Tsuji: Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett, 176(2), 149-58 (2002)) (Pubitemid 34136014)
99. K. Subramaniam, L. L. Ooi and K. M. Hui: Transcriptional down-regulation of IGFBP-3 in human hepatocellular carcinoma cells is mediated by the binding of TIA-1 to its AT-rich element in the 3'-untranslated region. Cancer Lett, 297(2), 259-68 (2010))
100. A. T. De Souza, G. R. Hankins, M. K. Washington, T. C. Orton and R. L. Jirtle: M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet, 11(4), 447-9 (1995))
101. Z. Piao, Y. Choi, C. Park, W. J. Lee, J. H. Park and H. Kim: Deletion of the M6P/IGF2r gene in primary hepatocellular carcinoma. Cancer Lett, 120(1), 39-43 (1997)) (Pubitemid 27483309)
102. X. Li, G. Adam, H. Cui, B. Sandstedt, R. Ohlsson and T. J. Ekstrom: Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene, 11(2), 221-9 (1995))
103. M. Suzuki, M. Kato, C. Yuyan, J. Takita, M. Sanada, Y. Nannya, G. Yamamoto, A. Takahashi, H. Ikeda, H. Kuwano, S. Ogawa and Y. Hayashi: Whole-genome profiling of chromosomal aberrations in hepatoblastoma using high-density single-nucleotide polymorphism genotyping microarrays. Cancer Sci, 99(3), 564-70 (2008)) (Pubitemid 351228574)
104. N. Akutsu, H. Yamamoto, S. Sasaki, H. Taniguchi, Y. Arimura, K. Imai and Y. Shinomura: Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. World J Gastroenterol, 16(28), 3521-8 (2010))
105. Y. C. Wang, Y. L. Chen, R. H. Yuan, H. W. Pan, W. C. Yang, H. C. Hsu and Y. M. Jeng: Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. Carcinogenesis, 31(9), 1516-22 (2010))
106. V. Tovar, C. Alsinet, A. Villanueva, Y. Hoshida, D. Y. Chiang, M. Sole, S. Thung, S. Moyano, S. Toffanin, B. Minguez, L. Cabellos, J. Peix, M. Schwartz, V. Mazzaferro, J. Bruix and J. M. Llovet: IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF- 1R blockage. J Hepatol, 52(4), 550-9 (2010))
107. C. E. Rogler, D. Yang, L. Rossetti, J. Donohoe, E. Alt, C. J. Chang, R. Rosenfeld, K. Neely and R. Hintz: Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem, 269(19), 13779-84 (1994))
108. D. Sachdev, X. Zhang, I. Matise, M. Gaillard-Kelly and D. Yee: The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene, 29(2), 251-62 (2010))
109. Y. W. Chen, V. Boyartchuk and B. C. Lewis: Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells. Neoplasia, 11(9), 835-45 (2009))
110. T. Nussbaum, J. Samarin, V. Ehemann, M. Bissinger, E. Ryschich, A. Khamidjanov, X. Yu, N. Gretz, P. Schirmacher and K. Breuhahn: Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology, 48(1), 146-56 (2008)) (Pubitemid 351975539)
111. J. A. Price, S. J. Kovach, T. Johnson, L. G. Koniaris, P. A. Cahill, J. V. Sitzmann and I. H. McKillop: Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatology, 36(5), 1089-97 (2002)) (Pubitemid 35253424)
112. S. M. de la Monte, S. Tamaki, M. C. Cantarini, N. Ince, M. Wiedmann, J. J. Carter, S. A. Lahousse, S. Califano, T. Maeda, T. Ueno, A. D'Errico, F. Trevisani and J. R. Wands: Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol, 44(5), 971-83 (2006))
113. E. Aleem, D. Nehrbass, F. Klimek, D. Mayer and P. Bannasch: Upregulation of the Insulin Receptor and Type I Insulin-Like Growth Factor Receptor Are Early Events in Hepatocarcinogenesis. Toxicol Pathol (2011))
114. Y. Tomimaru, H. Eguchi, H. Wada, S. Kobayashi, S. Marubashi, M. Tanemura, K. Umeshita, T. Kim, K. Wakasa, Y. Doki, M. Mori and H. Nagano: IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. Int J Cancer (2011))
115. Y. Tomimaru, H. Eguchi, H. Wada, T. Noda, M. Murakami, S. Kobayashi, S. Marubashi, Y. Takeda, M. Tanemura, K. Umeshita, Y. Doki, M. Mori and H. Nagano: Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells. Br J Cancer, 102(10), 1483-90 (2010))
116. S. Bai, M. W. Nasser, B. Wang, S. H. Hsu, J. Datta, H. Kutay, A. Yadav, G. Nuovo, P. Kumar and K. Ghoshal: MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem, 284(46), 32015-27 (2009))
117. C. Zeng, R. Wang, D. Li, X. J. Lin, Q. K. Wei, Y. Yuan, Q. Wang, W. Chen and S. M. Zhuang: A novel GSK-3 beta- C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology, 52(5), 1702-12 (2010))
118. M. Breinig, E. Caldas-Lopes, B. Goeppert, M. Malz, R. Rieker, F. Bergmann, P. Schirmacher, M. Mayer, G. Chiosis and M. A. Kern: Targeting heat shock protein 90 with nonquinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology, 50(1), 102-12 (2009))
119. C. Desbois-Mouthon, A. Baron, M. J. Blivet-Van Eggelpoel, L. Fartoux, C. Venot, F. Bladt, C. Housset and O. Rosmorduc: Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res, 15(17), 5445-56 (2009))
120. C. Desbois-Mouthon, W. Cacheux, M. J. Blivet-Van Eggelpoel, V. Barbu, L. Fartoux, R. Poupon, C. Housset and O. Rosmorduc: Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer, 119(11), 2557-66 (2006)) (Pubitemid 44691308)
121. H. Huynh, V. C. Ngo, H. N. Koong, D. Poon, S. P. Choo, H. C. Toh, C. H. Thng, P. Chow, H. S. Ong, A. Chung, B. C. Goh, P. D. Smith and K. C. Soo: AZD6244 enhances the antitumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol, 52(1), 79-87 (2010))
122. C. J. Weng, Y. H. Hsieh, C. M. Tsai, Y. H. Chu, K. C. Ueng, Y. F. Liu, Y. H. Yeh, S. C. Su, Y. C. Chen, M. K. Chen and S. F. Yang: Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol, 17(7), 1808-15 (2010))
123. J. Qian, D. Yao, Z. Dong, W. Wu, L. Qiu, N. Yao, S. Li, Y. Bian, Z. Wang and G. Shi: Characteristics of hepatic igf-ii expression and monitored levels of circulating igf-ii mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol, 134(5), 799-806 (2010))
124. W. W. Su, K. T. Lee, Y. T. Yeh, M. S. Soon, C. L. Wang, M. L. Yu and S. N. Wang: Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal, 24(3), 195-200 (2010))
125. M. Hewish, I. Chau and D. Cunningham: Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov, 4(1), 54-72 (2009))
126. B. J. Nieves, P. A. D'Amore and B. A. Bryan: The function of vascular endothelial growth factor. Biofactors, 35(4), 332-7 (2009))
127. C. F. Calvo, R. H. Fontaine, J. Soueid, T. Tammela, T. Makinen, C. Alfaro-Cervello, F. Bonnaud, A. Miguez, L. Benhaim, Y. Xu, M. J. Barallobre, I.
128. H. Gerhardt: VEGF and endothelial guidance in angiogenic sprouting. Organogenesis, 4(4), 241-6 (2008))
129. S. Hiratsuka: Vasculogenensis, angiogenesis and special features of tumor blood vessels. Front Biosci, 16, 1413-27 (2011))
130. K. Takenaga: Angiogenic signaling aberrantly induced by tumor hypoxia. Front Biosci, 16, 31-48 (2011))
131. K. Nakamura, Y. Zen, Y. Sato, K. Kozaka, O. Matsui, K. Harada and Y. Nakanuma: Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor- 1alpha are involved in malignant transformation in dysplastic nodules of the liver. Hum Pathol, 38(10), 1532-46 (2007)) (Pubitemid 47418965)
132. R. Yamaguchi, H. Yano, A. Iemura, S. Ogasawara, M. Haramaki and M. Kojiro: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology, 28(1), 68-77 (1998)) (Pubitemid 28299987)
133. V. R. Mas, D. G. Maluf, K. J. Archer, K. C. Yanek and R. A. Fisher: Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation, 84(10), 1262-71 (2007)) (Pubitemid 351339314)
134. Z. Z. Dong, D. F. Yao, W. Wu, M. Yao, H. B. Yu, J. J. Shen, L. W. Qiu, N. H. Yao, W. L. Sai and J. L. Yang: Delayed hepatocarcinogenesis through antiangiogenic intervention in the nuclear factor-kappa B activation pathway in rats. Hepatobiliary Pancreat Dis Int, 9(2), 169-74 (2010))
135. M. Berge, D. Allanic, P. Bonnin, C. D. Montrion, J. Richard, M. Suc, J. F. Boivin, J. O. Contreres, B. P. Lockhart, M. Pocard, B. I. Levy, G. C. Tucker, G. Tobelem and T. Merkulova-Rainon: Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodelling. J Hepatol (2011))
136. G. Chen, Y. Wang, M. Zhou, H. Shi, Z. Yu, Y. Zhu and F. Yu: EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma. Oncol Rep, 23(2), 563-70 (2010))
137. K. Kaji, H. Yoshiji, M. Kitade, Y. Ikenaka, R. Noguchi, Y. Shirai, J. Yoshii, K. Yanase, T. Namisaki, M. Yamazaki, T. Tsujimoto, H. Kawaratani and H. Fukui: Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. Hepatol Res, 40(5), 540-9 (2010))
138. T. Kanda, R. Steele, R. Ray and R. B. Ray: Hepatitis C virus core protein augments androgen receptor-mediated signaling. J Virol, 82(22), 11066-72 (2008))
139. Z. Lian, J. Liu, M. Wu, H. Y. Wang, P. Arbuthnot, M. Kew and M. A. Feitelson: Hepatitis B x antigen upregulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. Hepatology, 45(6), 1390-9 (2007))
140. L. P. Liu, H. F. Liang, X. P. Chen, W. G. Zhang, S. L. Yang, T. Xu and L. Ren: The role of NF-kappaB in Hepatitis b virus X protein-mediated upregulation of VEGF and MMPs. Cancer Invest, 28(5), 443-51 (2010))
141. A. Giacalone, G. Montalto, L. Giannitrapani, D. Balasus, A. Terranova, M. Cervello, M. Soresi and L. Marasa: Association Between Single Nucleotide Polymorphisms in the Cyclooxygenase-2, Tumor Necrosis Factor-alpha, and Vascular Endothelial Growth Factor-A Genes, and Susceptibility to Hepatocellular Carcinoma. OMICS, 15(3), 193-6 (2011))
142. Y. He, J. Ni, S. Chen, Y. Jiang, S. Jia and Y. Gao: The vascular endothelial growth factor-2549 insertion/deletion polymorphism is not associated with susceptibility to hepatocellular carcinoma in Chinese. DNA Cell Biol, 29(7), 393-6 (2010))
143. J. Cui, B. W. Dong, P. Liang, X. L. Yu and D. J. Yu: Construction and clinical significance of a predictive system for prognosis of hepatocellular carcinoma. World J Gastroenterol, 11(20), 3027-33 (2005)) (Pubitemid 40790657)
144. F. Aucejo, R. Kim, N. Zein, C. Quintini, T. D. Uso, R. Lopez, B. Eghtesad, J. Fung, C. Miller and L. Yerian: Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria. Liver Transpl, 15(2), 169-76 (2009))
145. J. Huang, X. Zhang, Q. Tang, F. Zhang, Y. Li, Z. Feng and J. Zhu: Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol, 64(4), 343-8 (2011))
146. M. C. Ho, C. N. Chen, H. Lee, F. J. Hsieh, C. T. Shun, C. L. Chang, Y. T. Lai and P. H. Lee: Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett, 250(2), 237-49 (2007)) (Pubitemid 46529444)
147. J. B. Jia, P. Y. Zhuang, H. C. Sun, J. B. Zhang, W. Zhang, X. D. Zhu, Y. Q. Xiong, H. X. Xu and Z. Y. Tang: Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol, 135(6), 847-54 (2009))
148. P. Ferroni, A. Spila, R. D'Alessandro, F. Martini, F. Iacovone, G. M. Ettorre, G. Vennarecci, R. Santoro, C. Puoti and F. Guadagni: Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer. Clin Chim Acta, 412(5-6), 450-4 (2011))
149. N. A. Gadelhak, S. A. Gadelhak, D. A. El-Morsi, M. M. Abdelaziz, A. T. Abbas and H. M. El-Emshaty: Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma. Hepatogastroenterology, 56(94-95), 1417-24 (2009))
150. A. O. Kaseb, M. M. Hassan, E. Lin, L. Xiao, V. Kumar, P. Pathak, R. Lozano, A. Rashid, J. L. Abbruzzese and J. S. Morris: V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer (2010))
151. S. Nagaoka, T. Yoshida, J. Akiyoshi, J. Akiba, T. Hisamoto, Y. Yoshida, M. Abe, H. Koga, T. Toirimura, T. Ueno and M. Sata: The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol Rep, 23(6), 1647-54 (2010))
152. J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J. F. Blanc, A. C. de Oliveira, A. Santoro, J. L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T. F. Greten, P. R. Galle, J. F. Seitz, I. Borbath, D. Haussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis and J. Bruix: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359(4), 378-90 (2008))
153. M. Kudo and K. Ueshima: Positioning of a moleculartargeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology, 78 Suppl 1, 154-66 (2010))
154. A. C. Piguet, B. Saar, R. Hlushchuk, M. V. St-Pierre, P. M. McSheehy, V. Radojevic, M. Afthinos, L. Terracciano, V. Djonov and J. F. Dufour: Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther (2011))
155. H. Huynh, V. C. Ngo, J. Fargnoli, M. Ayers, K. C. Soo, H. N. Koong, C. H. Thng, H. S. Ong, A. Chung, P. Chow, P. Pollock, S. Byron and E. Tran: Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res, 14(19), 6146-53 (2008))
156. J. W. Park, R. S. Finn, J. S. Kim, M. Karwal, R. K. Li, F. Ismail, M. B. Thomas, R. Harris, C. Baudelet, I. Walters and J. Raoul: Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma. Clin Cancer Res (2011))
157. V. J. Jasinghe, Z. Xie, J. Zhou, J. Khng, L. F. Poon, P. Senthilnathan, K. B. Glaser, D. H. Albert, S. K. Davidsen and C. S. Chen: ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J Hepatol, 49(6), 985-97 (2008))
158. K. Kudo, T. Arao, K. Tanaka, T. Nagai, K. Furuta, K. Sakai, H. Kaneda, K. Matsumoto, D. Tamura, K. Aomatsu, M. A. De Velasco, Y. Fujita, N. Saijo, M. Kudo and K. Nishio: Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo. Clin Cancer Res, 17(6), 1373-81 (2011))
159. M. Murakami, S. Kobayashi, S. Marubashi, Y. Tomimaru, T. Noda, H. Wada, H. Eguchi, Y. Takeda, M. Tanemura, K. Umeshita, Y. Doki, M. Mori and H. Nagano: Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-alpha/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol, 18(2), 589-96 (2011))
160. H. Iwamoto, T. Torimura, T. Nakamura, O. Hashimoto, K. Inoue, J. Kurogi, T. Niizeki, R. Kuwahara, M. Abe, H. Koga, H. Yano, R. S. Kerbel, T. Ueno and M. Sata: Metronomic s-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. Neoplasia, 13(3), 187-97 (2011))
161. K. Okamoto, D. Neureiter, B. Alinger, M. Meissnitzer, G. Sass, V. Schmitz, P. Di Fazio, T. Wissniowski, S. Gahr, B. Hohenstein, B. Kaufmann, A. Schlosser, U. Haus, E. G. Hahn, C. Herold and M. Ocker: The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. Int J Oncol, 33(4), 733-42 (2008))
162. Y. L. Chung, J. J. Jian, S. H. Cheng, S. Y. Tsai, V. P. Chuang, T. Soong, Y. M. Lin and C. F. Horng: Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res, 12(9), 2706-15 (2006))
163. K. A. Perry, C. K. Enestvedt, L. W. Hosack, T. H. Pham, B. S. Diggs, S. Teh, S. Orloff, S. Winn, J. G. Hunter and B. C. Sheppard: Increased vascular endothelial growth factor transcription in residual hepatocellular carcinoma after open versus laparoscopic hepatectomy in a small animal model. Surg Endosc, 24(5), 1151-7 (2010))
164. N. Turner and R. Grose: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer, 10(2), 116-29 (2010))
165. N. Itoh: Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res, 342(1), 1-11 (2010))
166. L. Dailey, D. Ambrosetti, A. Mansukhani and C. Basilico: Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev, 16(2), 233-47 (2005)) (Pubitemid 40616120)
167. N. Asada, Y. Tanaka, Y. Hayashido, S. Toratani, M. Kan, M. Kitamoto, T. Nakanishi, G. Kajiyama, K. Chayama and T. Okamoto: Expression of fibroblast growth factor receptor genes in human hepatoma-derived cell lines. In Vitro Cell Dev Biol Anim, 39(7), 321-8 (2003)) (Pubitemid 38200255)
168. X. Huang, C. Yang, C. Jin, Y. Luo, F. Wang and W. L. McKeehan: Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol Carcinog, 48(6), 553-62 (2009))
169. J. P. Lai, D. S. Sandhu, C. Yu, T. Han, C. D. Moser, K. K. Jackson, R. B. Guerrero, I. Aderca, H. Isomoto, M. M. Garrity-Park, H. Zou, A. M. Shire, D. M. Nagorney, S. O. Sanderson, A. A. Adjei, J. S. Lee, S. S. Thorgeirsson and L. R. Roberts: Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology, 47(4), 1211-22 (2008)) (Pubitemid 351547907)
170. J. P. Lai, J. R. Chien, D. R. Moser, J. K. Staub, I. Aderca, D. P. Montoya, T. A. Matthews, D. M. Nagorney, J. M. Cunningham, D. I. Smith, E. L. Greene, V. Shridhar and L. R. Roberts: hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology, 126(1), 231-48 (2004)) (Pubitemid 38040739)
171. C. Gauglhofer, S. Sagmeister, W. Schrottmaier, C. Fischer, C. Rodgarkia-Dara, T. Mohr, S. Stattner, C. Bichler, D. Kandioler, F. Wrba, R. Schulte-Hermann, K. Holzmann, M. Grusch, B. Marian, W. Berger and B. Grasl Kraupp: Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology, 53(3), 854-64 (2011))
172. X. Huang, C. Yu, C. Jin, C. Yang, R. Xie, D. Cao, F. Wang and W. L. McKeehan: Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog, 45(12), 934-42 (2006)) (Pubitemid 44907383)
173. K. H. Song, T. Li, E. Owsley, S. Strom and J. Y. Chiang: Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology, 49(1), 297-305 (2009))
174. K. Nicholes, S. Guillet, E. Tomlinson, K. Hillan, B. Wright, G. D. Frantz, T. A. Pham, L. Dillard-Telm, S. P. Tsai, J. P. Stephan, J. Stinson, T. Stewart and D. M. French: A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol, 160(6), 2295-307 (2002)) (Pubitemid 34663420)
175. X. Wu, H. Ge, B. Lemon, S. Vonderfecht, J. Weiszmann, R. Hecht, J. Gupte, T. Hager, Z. Wang, R. Lindberg and Y. Li: FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem, 285(8), 5165-70 (2010))
176. Y. Luo, C. Yang, W. Lu, R. Xie, C. Jin, P. Huang, F. Wang and W. L. McKeehan: Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. J Biol Chem, 285(39), 30069-78 (2010))
177. L. R. Desnoyers, R. Pai, R. E. Ferrando, K. Hotzel, T. Le, J. Ross, R. Carano, A. D'Souza, J. Qing, I. Mohtashemi, A. Ashkenazi and D. M. French: Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene, 27(1), 85-97 (2008))
178. H. Tsunematsu, T. Tatsumi, K. Kohga, M. Yamamoto, H. Aketa, T. Miyagi, A. Hosui, N. Hiramatsu, T. Kanto, N. Hayashi and T. Takehara: Fibroblast growth factor-2 enhances NK sensitivity of hepatocellular carcinoma cells. Int J Cancer (2011))
179. H. K. Ho, S. Pok, S. Streit, J. E. Ruhe, S. Hart, K. S. Lim, H. L. Loo, M. O. Aung, S. G. Lim and A. Ullrich: Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol, 50(1), 118-27 (2009))
180. N. Harimoto, K. Taguchi, K. Shirabe, E. Adachi, Y. Sakaguchi, Y. Toh, T. Okamura, H. Kayashima, A. Taketomi and Y. Maehara: The significance of fibroblast growth factor receptor 2 expression in differentiation of hepatocellular carcinoma. Oncology, 78(5-6), 361-8 (2010))
181. T. Amann, F. Bataille, T. Spruss, K. Dettmer, P. Wild, C. Liedtke, M. Muhlbauer, P. Kiefer, P. J. Oefner, C. Trautwein, A. K. Bosserhoff and C. Hellerbrand: Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am J Pathol, 176(3), 1433-42 (2010))
182. W. H. Qiu, B. S. Zhou, P. G. Chu, W. G. Chen, C. Chung, J. Shih, P. Hwu, C. Yeh, R. Lopez and Y. Yen: Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol, 11(34), 5266-72 (2005)) (Pubitemid 41410290)
183. H. D. Sun, M. Malabunga, J. R. Tonra, R. DiRenzo, F. E. Carrick, H. Zheng, H. R. Berthoud, O. P. McGuinness, J. Shen, P. Bohlen, R. L. Leibel and P. Kussie: Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am J Physiol Endocrinol Metab, 292(3), E964-76 (2007)) (Pubitemid 46411078)
184. K. Cao, W. Liu, H. Nakamura, H. Enomoto, T. Yamamoto, M. Saito, H. Imanishi, S. Shimomura, P. Cao and S. Nishiguchi: Vitamin K2 downregulates the expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma cells. Hepatol Res, 39(11), 1108-17 (2009))
185. N. Hotta, M. Ayada, K. Sato, T. Ishikawa, A. Okumura, E. Matsumoto, T. Ohashi and S. Kakumu: Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology, 54(79), 2073-7 (2007))
186. R. H. Alvarez, H. M. Kantarjian and J. E. Cortes: Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc, 81(9), 1241-57 (2006)) (Pubitemid 44316290)
187. H. Lei and A. Kazlauskas: Focus on molecules: platelet-derived growth factor C, PDGF-C. Exp Eye Res, 86(5), 711-2 (2008)) (Pubitemid 351618412)
188. Z. Wang, A. Ahmad, Y. Li, D. Kong, A. S. Azmi, S. Banerjee and F. H. Sarkar: Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta, 1806(1), 122-30 (2010))
189. C. V. Ustach and H. R. Kim: Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Molecular and cellular biology, 25(14), 6279-88 (2005)) (Pubitemid 40946575)
190. K. Breitkopf, C. Roeyen, I. Sawitza, L. Wickert, J. Floege and A. M. Gressner: Expression patterns of PDGFA, -B, -C and -D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cells (HSC). Cytokine, 31(5), 349-57 (2005)) (Pubitemid 41188056)
191. A. R. Simon, S. Takahashi, M. Severgnini, B. L. Fanburg and B. H. Cochran: Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol, 282(6), L1296-304 (2002)) (Pubitemid 34654586)
192. J. M. Llovet, Y. Chen, E. Wurmbach, S. Roayaie, M. I. Fiel, M. Schwartz, S. N. Thung, G. Khitrov, W. Zhang, A. Villanueva, C. Battiston, V. Mazzaferro, J. Bruix, S. Waxman and S. L. Friedman: A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology, 131(6), 1758-67 (2006)) (Pubitemid 46001394)
193. P. Stock, D. Monga, X. Tan, A. Micsenyi, N. Loizos and S. P. Monga: Platelet-derived growth factor receptoralpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther, 6(7), 1932-41 (2007)) (Pubitemid 47052483)
194. T. V. Bagnyukova, V. P. Tryndyak, L. Muskhelishvili, S. A. Ross, F. A. Beland and I. P. Pogribny: Epigenetic downregulation of the suppressor of cytokine signaling 1 (Socs1) gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficiency in rats. Cell Cycle, 7(20), 3202-10 (2008))
195. A. N. Fischer, E. Fuchs, M. Mikula, H. Huber, H. Beug and W. Mikulits: PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene, 26(23), 3395-405 (2007)) (Pubitemid 46788880)
196. J. Gotzmann, A. N. Fischer, M. Zojer, M. Mikula, V. Proell, H. Huber, M. Jechlinger, T. Waerner, A. Weith, H. Beug and W. Mikulits: A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene, 25(22), 3170-85 (2006)) (Pubitemid 43881558)
197. C. Lahsnig, M. Mikula, M. Petz, G. Zulehner, D. Schneller, F. van Zijl, H. Huber, A. Csiszar, H. Beug and W. Mikulits: ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression. Oncogene, 28(5), 638-50 (2009))
198. J. S. Campbell, S. D. Hughes, D. G. Gilbertson, T. E. Palmer, M. S. Holdren, A. C. Haran, M. M. Odell, R. L. Bauer, H. P. Ren, H. S. Haugen, M. M. Yeh and N. Fausto: Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A, 102(9), 3389-94 (2005)) (Pubitemid 40328055)
199. J. S. Campbell, M. M. Johnson, R. L. Bauer, K. L. Hudkins, D. G. Gilbertson, K. J. Riehle, M. M. Yeh, C. E. Alpers and N. Fausto: Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation, 75(9), 843-52 (2007)) (Pubitemid 350086173)
200. T. Maass, F. R. Thieringer, A. Mann, T. Longerich, P. Schirmacher, D. Strand, T. Hansen, P. R. Galle, A. Teufel and S. Kanzler: Liver specific overexpression of plateletderived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer, 128(6), 1259-68 (2011))
201. S. A. Lang, C. Moser, S. Fichnter-Feigl, P. Schachtschneider, C. Hellerbrand, V. Schmitz, H. J. Schlitt, E. K. Geissler and O. Stoeltzing: Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology, 49(2), 523-32 (2009))
202. C. K. Lau, Z. F. Yang, D. W. Ho, M. N. Ng, G. C. Yeoh, R. T. Poon and S. T. Fan: An Akt/hypoxia-inducible factor- 1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res, 15(10), 3462-71 (2009))
203. R. M. Talaat: Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity. Viral Immunol, 23(2), 151-7 (2010))
204. B. Bierie and H. L. Moses: Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev, 21(1), 49-59 (2010))
205. C. Han, W. C. Bowen, G. Li, A. J. Demetris, G. K. Michalopoulos and T. Wu: Cytosolic phospholipase A2alpha and peroxisome proliferator-activated receptor gamma signaling pathway counteracts transforming growth factor beta-mediated inhibition of primary and transformed hepatocyte growth. Hepatology, 52(2), 644-55 (2010))
206. H. J. Lee, C. H. Yun, S. H. Lim, B. C. Kim, K. G. Baik, J. M. Kim, W. H. Kim and S. J. Kim: SRF is a nuclear repressor of Smad3-mediated TGF-beta signaling. Oncogene, 26(2), 173-85 (2007)) (Pubitemid 46095729)
207. A. Alisa, S. Boswell, A. A. Pathan, L. Ayaru, R. Williams and S. Behboudi: Human CD4(+) T cells recognize an epitope within alpha-fetoprotein sequence and develop into TGF-betaproducing CD4(+) T cells. J Immunol, 180(7), 5109-17 (2008))
208. H. Ogata, T. Chinen, T. Yoshida, I. Kinjyo, G. Takaesu, H. Shiraishi, M. Iida, T. Kobayashi and A. Yoshimura: Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3- mediated TGF-beta1 production. Oncogene, 25(17), 2520-30 (2006))
209. H. Taniguchi, N. Kato, M. Otsuka, T. Goto, H. Yoshida, Y. Shiratori and M. Omata: Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol, 72(1), 52-9 (2004)) (Pubitemid 37484743)
210. Y. Lu, L. Q. Wu, C. S. Li, S. G. Wang and B. Han: Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis. Hepatobiliary Pancreat Dis Int, 7(2), 174-8 (2008)) (Pubitemid 351524062)
211. H. J. Bae, J. W. Eun, J. H. Noh, J. K. Kim, K. H. Jung, H. J. Xie, W. S. Park, J. Y. Lee and S. W. Nam: Down-regulation of transforming growth factor beta receptor type III in hepatocellular carcinoma is not directly associated with genetic alterations or loss of heterozygosity. Oncol Rep, 22(3), 475-80 (2009))
212. A. Benetti, A. Berenzi, M. Gambarotti, E. Garrafa, M. Gelati, E. Dessy, N. Portolani, T. Piardi, S. M. Giulini, A. Caruso, G. Invernici, E. A. Parati, R. Nicosia and G. Alessandri: Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. Cancer Res, 68(20), 8626-34 (2008))
213. H. J. Baek, S. C. Lim, K. Kitisin, W. Jogunoori, Y. Tang, M. B. Marshall, B. Mishra, T. H. Kim, K. H. Cho, S. S. Kim and L. Mishra: Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology, 48(4), 1128-37 (2008))
214. K. Kitisin, N. Ganesan, Y. Tang, W. Jogunoori, E. A. Volpe, S. S. Kim, V. Katuri, B. Kallakury, M. Pishvaian, C. Albanese, J. Mendelson, M. Zasloff, A. Rashid, T. Fishbein, S. R. Evans, A. Sidawy, E. P. Reddy, B. Mishra, L. B. Johnson, K. Shetty and L. Mishra: Disruption of transforming growth factor-beta signaling through betaspectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene, 26(50), 7103-10 (2007)) (Pubitemid 350059676)
215. K. Herzer, A. Grosse-Wilde, P. H. Krammer, P. R. Galle and S. Kanzler: Transforming growth factor-betamediated tumor necrosis factor-related apoptosis-inducing ligand expression and apoptosis in hepatoma cells requires functional cooperation between Smad proteins and activator protein-1. Mol Cancer Res, 6(7), 1169-77 (2008))
216. B. C. Kim: FoxO3a mediates transforming growth factor-beta1-induced apoptosis in FaO rat hepatoma cells. BMB Rep, 41(10), 728-32 (2008))
217. S. Huang, X. He, J. Ding, L. Liang, Y. Zhao, Z. Zhang, X. Yao, Z. Pan, P. Zhang, J. Li, D. Wan and J. Gu: Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer, 123(4), 972-8 (2008)) (Pubitemid 352032429)
218. K. Kiyono, H. I. Suzuki, H. Matsuyama, Y. Morishita, A. Komuro, M. R. Kano, K. Sugimoto and K. Miyazono: Autophagy is activated by TGF-beta and potentiates TGFbeta- mediated growth inhibition in human hepatocellular carcinoma cells. Cancer Res, 69(23), 8844-52 (2009))
219. L. Caja, P. Sancho, E. Bertran, D. Iglesias-Serret, J. Gil and I. Fabregat: Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF- {beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4. Cancer Res, 69(19), 7595-602 (2009))
220. I. Carmona-Cuenca, C. Roncero, P. Sancho, L. Caja, N. Fausto, M. Fernandez and I. Fabregat: Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J Hepatol, 49(6), 965-76 (2008))
221. P. Sancho, E. Bertran, L. Caja, I. Carmona-Cuenca, M. M. Murillo and I. Fabregat: The inhibition of the epidermal growth factor (EGF) pathway enhances TGFbeta- induced apoptosis in rat hepatoma cells through inducing oxidative stress coincident with a change in the expression pattern of the NADPH oxidases (NOX) isoforms. Biochim Biophys Acta, 1793(2), 253-63 (2009))
222. L. Caja, P. Sancho, E. Bertran and I. Fabregat: Dissecting the effect of targeting the epidermal growth factor receptor on TGF-beta-induced-apoptosis in human hepatocellular carcinoma cells. J Hepatol (2010))
223. J. Li, H. Fu, C. Xu, Y. Tie, R. Xing, J. Zhu, Y. Qin, Z. Sun and X. Zheng: miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer, 10, 354 (2010))
224. H. Zhang, I. Ozaki, T. Mizuta, H. Hamajima, T. Yasutake, Y. Eguchi, H. Ideguchi, K. Yamamoto and S. Matsuhashi: Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene, 25(45), 6101-12 (2006)) (Pubitemid 44562408)
225. B. H. Sohn, I. Y. Park, J. J. Lee, S. J. Yang, Y. J. Jang, K. C. Park, D. J. Kim, D. C. Lee, H. A. Sohn, T. W. Kim, H. S. Yoo, J. Y. Choi, Y. S. Bae and Y. I. Yeom: Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter. Gastroenterology, 138(5), 1898-908 (2010))
226. M. Murata, K. Matsuzaki, K. Yoshida, G. Sekimoto, Y. Tahashi, S. Mori, Y. Uemura, N. Sakaida, J. Fujisawa, T. Seki, K. Kobayashi, K. Yokote, K. Koike and K. Okazaki: Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology, 49(4), 1203-17 (2009))
227. H. Nagata, E. Hatano, M. Tada, M. Murata, K. Kitamura, H. Asechi, M. Narita, A. Yanagida, N. Tamaki, S. Yagi, I. Ikai, K. Matsuzaki and S. Uemoto: Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma. Hepatology, 49(6), 1944-53 (2009))
228. S. H. Choi and S. B. Hwang: Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein. J Biol Chem, 281(11), 7468-78 (2006)) (Pubitemid 43847519)
229. Y. Yang, F. Zhou, Z. Fang, L. Wang, Z. Li, L. Sun, C. Wang, W. Yao, X. Cai, J. Jin and X. Zha: Posttranscriptional and post-translational regulation of PTEN by transforming growth factor-beta1. J Cell Biochem, 106(6), 1102-12 (2009))
230. H. Yildirim and F. Kockar: TGF-beta upregulates tumor-associated carbonic anhydrase IX gene expression in Hep3B cells. Cell Biol Int, 33(9), 1002-7 (2009))
231. T. Kou, H. Marusawa, K. Kinoshita, Y. Endo, I. M. Okazaki, Y. Ueda, Y. Kodama, H. Haga, I. Ikai and T. Chiba: Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int J Cancer, 120(3), 469-76 (2007)) (Pubitemid 44969015)
232. E. Fransvea, A. Mazzocca, S. Antonaci and G. Giannelli: Targeting transforming growth factor (TGF)- betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology, 49(3), 839-50 (2009))
233. E. Fransvea, U. Angelotti, S. Antonaci and G. Giannelli: Blocking transforming growth factor-beta upregulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology, 47(5), 1557-66 (2008)) (Pubitemid 351702739)
234. E. Fransvea, A. Mazzocca, A. Santamato, A. Azzariti, S. Antonaci and G. Giannelli: Kinase activation profile associated with TGF-beta-dependent migration of HCC cells: a preclinical study. Cancer Chemother Pharmacol (2010))
235. A. Mazzocca, E. Fransvea, F. Dituri, L. Lupo, S. Antonaci and G. Giannelli: Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology, 51(2), 523-34 (2010))
236. S. Dooley, H. Weng and P. R. Mertens: Hypotheses on the role of transforming growth factor-beta in the onset and progression of hepatocellular carcinoma. Dig Dis, 27(2), 93-101 (2009))
237. P. Qi, Y. M. Chen, H. Wang, M. Fang, Q. Ji, Y. P. Zhao, X. J. Sun, Y. Liu and C. F. Gao: -509C>T polymorphism in the TGF-beta1 gene promoter, impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection. Cancer Immunol Immunother, 58(9), 1433-40 (2009))
238. Z. Z. Dong, D. F. Yao, M. Yao, L. W. Qiu, L. Zong, W. Wu, X. H. Wu, D. B. Yao and X. Y. Meng: Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 7(3), 288-95 (2008)) (Pubitemid 351895389)
239. C. Coulouarn, V. M. Factor and S. S. Thorgeirsson: Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology, 47(6), 2059-67 (2008)) (Pubitemid 351945572)
240. T. Mamiya, K. Yamazaki, Y. Masugi, T. Mori, K. Effendi, W. Du, T. Hibi, M. Tanabe, M. Ueda, T. Takayama and M. Sakamoto: Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis. Lab Invest, 90(9), 1339-45 (2010))
241. A. Mazzocca, E. Fransvea, G. Lavezzari, S. Antonaci and G. Giannelli: Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology, 50(4), 1140-51 (2009))
242. S. A. Eccles: Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society- AACR Conference - Research on Metastasis: part 2. IDrugs, 13(11), 768-71 (2010))
243. U. Bogdahn, P. Hau, G. Stockhammer, N. K. Venkataramana, A. K. Mahapatra, A. Suri, A. Balasubramaniam, S. Nair, V. Oliushine, V. Parfenov, I. Poverennova, M. Zaaroor, P. Jachimczak, S. Ludwig, S. Schmaus, H. Heinrichs and K. H. Schlingensiepen: Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol, 13(1), 132-42 (2011))
244. K. H. Schlingensiepen, F. Jaschinski, S. A. Lang, C. Moser, E. K. Geissler, H. J. Schlitt, M. Kielmanowicz and A. Schneider: Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci, 102(6), 1193-200 (2011))
245. G. Giannelli, A. Mazzocca, E. Fransvea, M. Lahn and S. Antonaci: Inhibiting TGF-beta signaling in hepatocellular carcinoma. Biochim Biophys Acta, 1815(2), 214-23 (2011)